#United States #San Diego #Antengene #ADCs #TCEs

Antengene Highlights Its Innovative Programs at AACR 2026

Antengene Corporation Limited, a prominent biotech firm based in Shanghai and Hong Kong, is gearing up to present cutting-edge preclinical findings at the highly anticipated American Association for Cancer Research Annual Meeting (AACR 2026) scheduled from April 17 to 22, 2026, in San Diego, California. The company's research focuses on innovative cancer treatments, particularly First-in-class and Best-in-class medicines for solid tumors, hematological malignancies, and autoimmune diseases.

Presentation Overview

Antengene plans to showcase three notable projects during the event:

• - ATG-125: A bispecific antibody-drug conjugate (ADC) targeting B7-H3 and PD-L1, aimed at enhancing the therapy's effectiveness against solid tumors.
• - ATG-106: An investigational T cell engager (TCE) targeting CDH6, specifically developed for treating ovarian and kidney cancers.
• - ATG-112: Another TCE targeting ALPPL2, designed for a variety of cancers including gynecological tumors and non-small cell lung cancer (NSCLC).

Detailed Insights on the Projects

1. ATG-125 (B7-H3 x PD-L1 Bispecific ADC)

The first presentation will delve into ATG-125, which combines the targeting capabilities of B7-H3, a promising cancer biomarker, and PD-L1, a well-known immune checkpoint. This innovative design allows ATG-125 to simultaneously block immune evasion while delivering a cytotoxic payload directly to tumor cells. The study demonstrated that ATG-125 is effective in inducing tumor regression in xenograft models, indicating its potential as a next-generation cancer therapy.

2. ATG-106 (CDH6 x CD3 TCE)

Next, the spotlight shifts to ATG-106, a novel T cell engager designed with a steric hindrance mechanism that minimizes interactions with healthy cells while maximizing the attack on CDH6-positive tumor cells. This study will showcase preclinical data illustrating its substantial effectiveness in activating T cells and producing tumor regression in humanized animal models. Notably, the results suggest a favorable safety profile with reduced risks of cytokine release syndrome, a common side effect in cancer treatments.

3. ATG-112 (ALPPL2 x CD3 TCE)

Lastly, Antengene will discuss ATG-112, which targets ALPPL2 and is intended for treating multiple types of solid tumors. The findings indicate that this TCE not only binds effectively to tumor cells but also induces robust T cell-mediated cytotoxic responses with minimal adverse immune reactions. This project exemplifies Antengene’s commitment to advancing therapies that garner more effective and safer patient outcomes.

Antengene's Impact on the Biotech Landscape

Antengene has established itself as a key player in the biotechnology field, evidenced by a diverse pipeline that includes various innovative therapeutic candidates. Through their proprietary AnTenGager™ TCE platform, they aim to enhance the efficacy of T cell engagings across different tumor types while mitigating undesirable side effects. Their R&D efforts have already yielded significant investigational drug approvals, showcasing the company’s dedication to tackling unmet needs in medical treatment.

The AACR 2026 presentation is not just an exhibition of Antengene’s commitment to scientific advancement; it represents a crucial step toward making significant contributions to the field of oncology and autoimmune therapies. As researchers and healthcare professionals gather to share insights, Antengene stands ready to play a pivotal role in shaping the future of cancer treatment.

Antengene Corporation Limited continues to push the limits of scientific discovery. With a potent combination of innovation, research, and a strong vision for the future, the company is set to enhance the landscape of biotechnology.

For those interested in the latest advancements in cancer therapeutics, Antengene's insights at AACR 2026 promise to be compelling and invaluable.